Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7945

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907945)

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)
This text provides information about the results of a study comparing Atenolol and Losartan potassium in patients. The study shows an adjusted risk reduction of 13% for the primary endpoint with a p-value of 0.021 over a span of 66 study months.*
FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)
This document provides an analysis of the overall results of a study comparing the effectiveness of Atenolol and Losartan Potassium in certain patient populations based on age, gender, presence of diabetes, and history of cardiovascular disease. The study includes the event rates and hazard ratios for stroke (Fatal/Non-Fatal) for patients under different conditions. The findings suggest that Losartan Potassium may be favored over Atenolol in some instances based on the outcomes observed.*
FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)
This description shows the results of a study comparing the effectiveness of Losartan Potassium versus a Placebo in reducing the risk of an event. The study involved a group of patients, with a 16.1% risk reduction observed in the Losartan Potassium group compared to the Placebo group. The statistical significance of the results is indicated by a p-value of 0.022.*
FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.